A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED (NCT05966493)
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With Persistent Corneal Epithelial Defects (NEXPEDE-1)
🩺 Plain-English Summary (8th-Grade Level)
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.
Who can join: Review the eligibility criteria below.
Location: Glaukos Investigative Site — Dothan, Alabama
Age range: 2 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- Glaukos Investigative Site — Dothan, Alabama
- Glaukos Investigative Site — Petaluma, California
- Glaukos Investigative Site — Torrance, California
- Glaukos Investigative Site — Colorado Springs, Colorado
- Glaukos Investigative Site — Grand Junction, Colorado
- Glaukos Investigative Site — Bradenton, Florida
- Glaukos Investigative Site — Fort Myers, Florida
- Glaukos Investigative Site — South Miami, Florida
- Glaukos Investigative Site — Atlanta, Georgia
- Glaukos Investigative Site — Carmel, Indiana
- Glaukos Investigative Site — Fraser, Michigan
- Glaukos Investigative Site — Kansas City, Missouri
- Glaukos Investigative Site — Kansas City, Missouri
- Glaukos Investigative Site — Palisades Park, New Jersey
- Glaukos Investigative Site — Shelby, North Carolina
- Glaukos Investigative Site — Bala-Cynwyd, Pennsylvania
- Glaukos Investigative Site — Nashville, Tennessee
- Glaukos Investigative Site — Houston, Texas
- Glaukos Investigative Site — San Antonio, Texas
- Glaukos Investigative Site — Madison, Wisconsin
- Glaukos Investigative Site — Milwaukee, Wisconsin
- Glaukos Investigative Site — Mainz,
- Glaukos Investigative Site — München,
- Glaukos investigative Site — Messina,
- Glaukos Investigative Site — Barcelona,
📞 Contact the Study Coordinator
Phone: (949) 739-8749
Email: ClinicalResearch@Glaukos.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Persistent Corneal Epithelial Defect
- An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED — Huntington Beach, California
- Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease — Chicago, Illinois
Explore by condition: All Persistent Corneal Epithelial Defect clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.